We also observed that the level of serum androgen was significantly associated with the percentage of CD8+PD1+ T-cells, and a higher serum androgen predicted a worse prognosis in male RCC patients receiving immunotherapy. The gene discussed is CD8A; the disease is renal cell carcinoma.